New Orleans, LA, USA—May 22, 2019—ISPOR, the professional society for health economics and
outcomes research (HEOR), explored the possibility of health technology
assessment (HTA) in the United States this morning at its ISPOR
2019 annual
conference with the session [IP26], “Could Formal HTA Be a Solution to High
Healthcare Costs in the United States?”
The United States has the
highest healthcare costs per person in the world. HTA is often seen as a method
for drug cost control; however, the US healthcare system lacks a national HTA
body with a formal mandate and binding authority. A number of differences in
the US healthcare system complicate the issue, such as reimbursement
structures, stakeholder incentives, and a pluralistic payer system. The United
States’ notable absence of an HTA body contrasts markedly with other countries
where healthcare is more affordable. The increase in the number of institutions
in the United States that are developing value frameworks for assessment of
therapies could signal a greater willingness to accept formal HTA as part of
reimbursement.
Panelists for the session
included:
- Wrik Ghosh, MSc; Costello Medical Singapore Pte Ltd; Singapore
- Sarah Breen, MA, MSc; MSD UK; Hoddesdon, England, UK
- Thomas Butt, PhD; Peking University; Beijing, China
- Daniel A. Ollendorf, PhD; Tufts Medical Center; Boston, MA, USA
Dr Ollendorf provided an
HTA perspective, comparing the efforts made by the Institute for Clinical and
Economic Review (ICER) in the United States to those abroad, highlighting
feasible options. Dr Butt offered an international perspective, discussing
whether the United States can learn from countries that have successfully
implemented HTA or whether there are higher priorities for US healthcare
system. Ms Breen offered a manufacturer perspective, noting that formal HTA
could present a threat to manufacturers’ profits and change incentives, but could
also provide opportunities to demonstrate value and improve patient access.
ISPOR is recognized
globally as the leading professional society for health economics and outcomes
research and its role in improving healthcare decisions. ISPOR 2019 is the
leading global HEOR conference and draws nearly 4000 healthcare thought leaders
and stakeholders, including researchers and academicians, assessors and
regulators, payers and policy makers, the life sciences industry, healthcare
providers, and patient engagement organizations.
Additional information on the conference can be found at:
Conference Information | Program | Registration | Short Course Program | Sponsors | Exhibitors | Press
###
ABOUT ISPOR
ISPOR, the professional society for health economics
and outcomes research (HEOR), is an international, multistakeholder, nonprofit
dedicated to advancing HEOR excellence to improve decision making for health globally.
The Society is the leading source for scientific conferences, peer-reviewed and
MEDLINE®-indexed publications, good practices guidance, education,
collaboration, and tools/resources in the field.
Web: www.ispor.org | LinkedIn: www.linkedin.com/company/ispororg | Twitter: www.twitter.com/ispororg (@ISPORorg) | YouTube: www.youtube.com/ispororg | Facebook: www.facebook.com/ispororg | Instagram: www.instagram.com/ispororg